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The  underlying  cause  of  cervical  cancer  is an  infection  with  the  human  papilloma  virus  (HPV)  and  HPV
testing  can be used  for  cervical  cancer  screening.  The  Aptima  HPV  assay  from  Hologic  is an  mRNA  HPV  test
used  to identify  clinically  relevant  infections  but  the  method  does  not  discriminate  between  the different
high  risk  genotypes.  The  aim  of  the  current  study  was  to  evaluate  if  analyzed  Aptima  sample  transfer
tubes  could  be used  as  a source  for HPV  genotyping,  using  sample  DNA.  Study  samples  (n  = 108);  were
HPV-tested  with  mRNA  Aptima  assay  and in  parallel  DNA  was  extracted  and  genotyped  with  Anyplex  II
HPV28.  Analyzed  mRNA  Aptima  tubes  were  thereafter  used  as  source  for a second  DNA  extraction  and
genotyping.  Using  mRNA  Aptima  result  as  reference,  90%  of  the  samples  (35/39)  were  high  risk  positive
with  the  Anyplex  II HPV28.  Cohen’s  kappa  0.78  (95%  CI:  0.66–0.90),  sensitivity  0.90  (95% CI:  0.76–0.97)
and speciﬁcity  0.90  (95%  CI: 0.80–0.96).  Two  discordant  samples  carried low-risk  genotypes  (HPV  82 and
HPV  44)  and  two  were  negative.  DNA-genotyping  results,  in parallel  to and  after  mRNA  testing,  were
compared  and  differed  signiﬁcantly  (McNemar  test:  P = 0.021)  possibly  due  to sample  extraction  volume
difference.  Cohen’s  kappa  0.81  (95%  CI: 0.70–0.92),  sensitivity  0.85  (95%  CI: 0.74–0.93)  and  speciﬁcity
0.98 (95%  CI:  0.88–1.00).  In  conclusion,  analyzed  mRNA  Aptima  sample  tubes  could  be used as  a source
for  DNA  HPV  genotyping.  The  sample  volume  used  for extraction  needs  to be further  explored.
©  2016  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND. Introduction
The underlying cause of cervical cancer is infection with human
apilloma virus (HPV) (Walboomers et al., 1999). Despite the
act that the infection is quite common amongst young women,
nly a minor fraction of all infections will progress to precancer-
us lesions and cancer (Moscicki et al., 2012). Over 200 different
PV genotypes are described (International Human Papillomavirus
eference Center, Karolinska, 2016) and the mucosal genotypes are
urther classiﬁed as high risk, potential or probable high risk as well
s low risk types (Bzhalava et al., 2013). According to International
gency for Research of Cancer (IARC) (Anon, 2012), twelve types
re in the high risk strata (HPV-16, 18, 31, 33, 35, 39, 45, 51, 52,
6, 58, and 59) with HPV-16 and 18 accounting for about 70% of
ll cervical cancer cases (Bruni et al., 2014; Schiffman et al., 2007).
PV-66 and HPV-68 have also been proposed to be included in this
roup of high risk types (Bzhalava et al., 2013) together with addi-
∗ Corresponding author.
E-mail address: gabriella.lillsunde-larsson@regionorebrolan.se
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166-0934/© 2016 The Authors. Published by Elsevier B.V. This is an open access article 
/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
tional genotypes from the possible carcinogenic group (Bzhalava
et al., 2013; Arbyn et al., 2014).
In Sweden, as well as in other countries, HPV testing is suggested
as primary method for cervical cancer screening. In transforming
lesions, a deregulated viral oncoprotein expression is a prerequi-
site (Doorbar, 2006) and the Aptima HPV assay detects E6 and E7
mRNA with the aim to identify clinically relevant infections where
viral oncoprotein levels are high, relative to permissive infections
(Arbyn et al., 2012). Thus, since most HPV infections clear without
inducing cell dysplasia, HPV-testing struggles with clinical speci-
ﬁcity. To exclude false-positive cases and to identify the proportion
of women with an underlying cervical intraepithelial neoplasia
(CIN2+) and in need of treatment, triage testing is an alternative,
with either cytology or possibly also with genotyping after initial
high risk HPV-testing.
Additional genotype information is valuable from several per-
spectives (Choi and Park, 2016). The risk for developing neoplasia
may  vary with HPV genotype and in the long-term study by Smelov
et al. (2015), the 14-year cumulative incidence for CIN-3 in women
infected with the high risk types 16, 18, 31 and 33 was shown to be
above 28%. Therefore, information on speciﬁc genotypes could be
of outmost importance for patient treatment and follow-up (Jones
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Fig. 1. Design of study. mRNA Aptima test and DNA genotyping test Anyplex II
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aPV28 were initially performed in parallel on 108 samples. The analyzed mRNA
ptima tubes were then used as sample for the second DNA test, Anyplex post
ptima.
t al., 2011; Paraskevaidis et al., 2004; Zielinski et al., 2004). Also,
enotyping information can determine if follow-up samples hold a
ew or a persistent infection and it can also be valuable for follow-
ng the distribution in vaccinated cohorts.
The Aptima HPV assay from Hologic captures E6 and E7 mRNA
from the fourteen high risk genotypes) in the sample by a
ybridization process. This mRNA is then used in the following
nalysis but the method does not discriminate between the dif-
erent genotypes. Although the assay does not provide genotyping
etails, the analyzed sample tube could be a source for further
nvestigation. Sample DNA is kept in the Aptima sample transfer
ube and could therefore be a prospective target. It could be used for
everal purposes such as genotype determination, viral load esti-
ation as well as virus and host methylation analysis, all potential
ew biomarkers for triage testing of HPV-positive women. The aim
f this study was therefore to evaluate if DNA could be used as a
ource for further analysis in terms of direct HPV genotyping from
he analyzed Aptima sample transfer tubes. Using analyzed tubes
or further DNA analysis could offer a time efﬁcient alternative
ompared to retaining of the original sample.
. Material and methods
Study material consisted of 108 samples in total, 98 of them
ere liquid based ThinPrep cytology (LBC) samples from Örebro
ounty, Sweden. They were either from triage testing where pri-
ary vaginal cytology had resulted in ASCUS or CIN1 or follow
p samples consecutively collected during 2014. HPV-testing was
erformed in consensus to current national guidelines. Also, 10
amples from a HPV proﬁciency panel (clinical samples and cellines
n Preservcyt media) were included.
.1. Design of study
The design of the study is outlined in Fig. 1, and according to the
ormal algorithm in the laboratory, all samples were HPV-tested
ith the mRNA Aptima assay. This initial Aptima test was  used for
iagnostic purposes. Thereafter, samples and results were coded
nd anonymized and could not be connected to either personal data
r clinical evaluation. For this methodological study, no informed
onsent or ethical approval was obtained since anonymized patient
amples without any connection to patient data or patient identi-
ies were used.
In parallel to the mRNA Aptima assay, an additional 1 ml  of coded
ample from the Thinprep sample was extracted for DNA as well
s 200 l from the recollected analyzed Aptima tubes. Both DNAlogical Methods 235 (2016) 80–84 81
extractions were analyzed with a DNA-method for HPV genotyping
(Anyplex II HPV28) and named Anyplex in parallel and Anyplex post
Aptima.
2.2. mRNA analysis
1 ml  of each sample was  manually transferred to an Aptima
Specimen Transfer Tube and analyzed on the Panther system
(Hologic). The mRNA Aptima assay is a qualitative method for
detection of mRNA from 14 different high risk HPV (HPV-16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) using target capture
of E6 and E7. Capture oligomers target HPV mRNA, which is next
ampliﬁed with a transcription based method. First, A DNA copy is
produced functioning as a template for extensive RNA ampliﬁca-
tion and ﬁnally, probe hybridization is used for detection (Relative
Light Units, RLU). Controls are included to adjust cut-off level and
results are given as signal- to- cut-off (S/CO). An S/CO above 0.5
is considered a positive test result as determined automatically by
assay software. No human control gene is included.
2.3. DNA analysis
In parallel to the mRNA Aptima HPV testing, 1 ml from each LBC
or proﬁciency panel sample was used for DNA  extraction. Sam-
ple cells were pelleted and extraction performed with QiaAmp
DNA Minikit according to instructions by the manufacturer (Qiagen,
Hilden, Germany). After mRNA Aptima HPV testing had been per-
formed, test-tubes were recollected and 200 l of residual material
was used for DNA extraction. Again, the QiaAmp DNA Minikit (Qia-
gen) was used. Anyplex II HPV28 (Seegene, Korea) was used as DNA
HPV test for both extractions, and runs were named Anyplex in
parallel and Anyplex post Aptima.
The Anyplex II HPV28, an In Vitro Diagnosis Use (IVD) marked
assay, is a very sensitive real-time DNA assay with melting cure
analysis after 30, 40 and 50 cycles. The assay includes detection
of the same genotypes as the mRNA APTIMA as well as 14 addi-
tional types, i.e. HPV 26, 53, 66, 70, 73, 82, 6, 11, 40, 42, 43, 44, 54
and 61. A human control gene, HBB, is also included to verify cell
content. The CFX96TM Real-time PCR System (BioRad, Hercules,
USA) was  used for ampliﬁcation and reactions of 20 l were per-
formed in duplicate. Each reaction contained 1x HPV28 primer mix
A or B, 1x Anyplex Mastermix and 5 l of extracted DNA. The PCR
was initiated with a 4 min  step of 50 ◦C followed by 15 min  denat-
uration at 95 ◦C. Thereafter, 30 cycles with 95 ◦C at 30 s, 60 ◦C at
60 s and 72 ◦C at 30 s was performed with a completing melting
curve analysis at 55◦ to 85 ◦C (5s/0.5 ◦C). Cycling was continued
for 10 cycles followed be subsequent melting curve analysis (40
cycles) and this was once again repeated (50 cycles). In each run,
plasmid constructs of all HPV genotypes were included as positive
controls (n = 3). Sample results were analyzed using the Seegene
Viewer Software (Seegene) and results were semi-quantitatively
classiﬁed after result at 30 (+++), 40 (++) or 50 (+) cycles indicating
sample viral load. For a negative HPV result, human control gene
(HBB) has to be detected at either 30 (+++) or 40 cycles (++) accord-
ing to the manufacturer (Seegene) or else indicating inadequate
specimen collection. HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, 66 and 68 were considered as high risk positive genotypes in
the analysis.
2.4. StatisticsComparisons of DNA results were made using the McNemarı´s
test and by calculating Cohenı´s  kappa values, SPSS Statistics version
22 (IBM, New York, USA). Calculation of sensitivity and speciﬁcity
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Table 1
Concordance between the mRNA Aptima assay and high risk results from DNA
genotyping Anyplex II HPV 28 (Anyplex post Aptima). Genotypes in column 3 and
4  are followed by +, indicating a semi quantitative viral load. Detection after 30
cycles: +++ (high viral titer), after 40 cycles: ++ (intermediate viral titer) and after
50 cycles: + (low viral titer).
Sample APTIMA Anyplex II HPV 28
Conclusive result High risk genotype Low risk genotype
1 Positive Positive 16+
2  Positive Positive 16++
3  Positive Positive 16++
4  Positive Positive 16+
5  Positive Positive 16++
6  Positive Positive 16++
7  Positive Positive 16++
8  Positive Positive 16++
9  Positive Positive 16++
10 Positive Positive 16++
11 Positive Positive 16++
12 Positive Positive 16++, 56++
13  Positive Positive 16++, 56++
14  Positive Positive 18++
15 Positive Positive 18++
16 Positive Positive 18++, 16+
17  Positive Positive 31++
18 Positive Positive 31++
19 Positive Positive 31++
20 Positive Positive 31++
21 Positive Positive 31++
22 Positive Positive 33++
23 Positive Positive 35++, 58++
24  Positive Positive 39+++
25 Positive Positive 39++, 45+
26  Positive Positive 39+++, 45+
27 Positive Positive 45++
28 Positive Positive 45++
29 Positive Positive 59++
30 Positive Positive 66++
31 Positive Positive 66++
32 Positive Positive 66++
33 Positive Positive 66++
34 Positive Positive 66+++, 35++
35 Positive Positive 68+++
36 Positive Negative 44++
37  Positive Negative
38 Positive Negative 82+
39  Positive Negative
40 Negative Positive 16+
41 Negative Positive 31+
42 Negative Positive 33++
43 Negative Positive 51+++
44 Negative Positive 58+2 G. Lillsunde Larsson et al. / Journal 
ith 95% conﬁdence interval was made by GraphPad Prism ver. 6
GraphPad, La Jolla CA, USA).
. Results
Results were calculated from a total of 107 sample results due to
ne invalid sample in the Anyplex post Aptima run. This sample had
 negative HPV-result and a non-valid human control gene result.
.1. Detection of high risk genotypes from mRNA Aptima positive
amples
Thirty-seven percent (39/107) of the collected samples were
ositive using the mRNA Aptima HPV assay while 39% (42/107)
ere positive for one or more high risk HPV with the Anyplex II
PV28 DNA genotyping assay performed after the mRNA Aptima
PV assay from the extracted test tubes (Anyplex post Aptima).
sing the mRNA Aptima result as reference, 90% of the samples
35/39) were also high risk positive with the Anyplex II HPV28.
PV 16 was the most frequent genotype (n = 14) followed by HPV
1 (n = 5) and HPV 66 (n = 5). Cohen’s kappa value was  calculated to
.78 (95% CI: 0.66–0.90), sensitivity 0.90 (95% CI: 0.76–0.97) and
peciﬁcity was 0.90 (95% CI: 0.80–0.96). Of the 4 disconcordant
RNA positive but high risk DNA negative samples, two samples
ere detected as low-risk genotypes (HPV 82 and HPV 44) and two
ere negative.
Seven of the mRNA Aptima negative samples were positive in
he Anyplex II HPV28 DNA genotyping performed after the mRNA
ptima assay (Anyplex post Aptima). Samples were found to con-
ain genotypes 16, 31, 33, 51, 56 and 58 at 30, 40 and 50 cycles, see
able 1 for details.
.2. DNA genotyping in parallel to and post Aptima
Fifty-eight percent (62/107) of the samples were positive for
ny of the HPV genotypes (high and low risk genotypes) using the
nyplex assay in parallel to mRNA Aptima assay and 50% (54/107)
f the samples were positive after the mRNA Aptima assay had been
erformed (Anyplex post Aptima). A signiﬁcant difference between
PV DNA-positive results in Anyplex in parallel and Anyplex post
ptima was found (McNemar test: P = 0.021). Cohen’s kappa value
as calculated to 0.81 (95% CI: 0.70–0.92). Agreement of sample
esults (Anyplex in parallel and Anyplex post Aptima) was 91%,
ensitivity 0.85 (95% CI: 0.74–0.93) while speciﬁcity was 0.98 (95%
I: 0.88–1.00).
Forty-seven percent (50/107) of the samples from the paral-
el Anyplex run were positive for one or more high risk genotype
nd 11% (12/107) for one or more low risk genotype (without any
igh risk genotype detected). In Anyplex post Aptima, thirty-nine
ercent (42/107) were positive for one or more high risk HPV and
1% (12/107) for one or more low risk genotype. A signiﬁcant dif-
erence between high risk HPV DNA-positive samples in Anyplex
n parallel and Anyplex post Aptima was found (McNemar test:
 = 0.021). Cohen’s kappa value was calculated to 0.81 (95% CI:
.70–0.92). Agreement of high risk sample results (Anyplex in par-
llel and Anyplex post Aptima) was 91%, sensitivity 0.82 (95% CI:
.69–0.91) while speciﬁcity was 0.98 (95% CI: 0.91–1.00). Nine of
he previously high risk positive samples (detectable either after
0 or 50 cycles) were after Aptima detected either as low risk posi-
ives (n = 3) or negatives (n = 6). As a comparison, the parallel mRNA
ptima HPV result for the same samples were negative in 8 of 9
ases. One sample that was negative for high risk HPV in the par-
llel Anyplex run was found to be positive in Anyplex post Aptima,
able 2.
In the parallel Anyplex run, a total of 65 high risk genotyping
esults were found. The most common high risk genotype was  HPV-45 Negative Positive 58+
46 Negative Positive 56+
16 followed by HPV-66, Table 3. Altogether, thirty of the high risk
results detected in Anyplex in parallel were detected at the same
cycle number (detection level) in Anyplex post Aptima. Twenty
of the high risk results were detected at a lower detection level,
either a change from 30 to 40 cycles (n = 13) or from 40 to 50 cycles
(n = 7). Fourteen high risk results were not detected in Anyplex post
Aptima, Table 3. Five of them were previously detected at 40 cycles
and nine were previously detected at 50 cycles.
There were several different combinations of high and low risk
genotypes and for HPV-16, this genotype was  accompanied with
both HPV-53 (n = 3), HPV-42 (n = 2), HPV-73 (n = 2), HPV-6 (n = 2),
HPV-44 (n = 1) and HPV- 61 (n = 1).
4. DiscussionThis methodological study shown it possible to use the pro-
cessed mRNA Aptima transfer sample tube as a source for DNA
analysis, i.e. for HPV genotyping. In the clinical setting, a simple
G. Lillsunde Larsson et al. / Journal of Virological Methods 235 (2016) 80–84 83
Table  2
Detailed genotyping results for discordant samples. Comparison of high risk positive samples from HPV DNA genotyping Anyplex in parallel and post Aptima. Detection levels
are  given for both human control gene HBB and the different HPV high risk genotypes and speciﬁed as positive at 30 cycles (+++; high viral titer), 40 cycles (++; intermediate
viral  titer) and 50 cycles (+; low viral titer).
Anyplex in parallel Anyplex post Aptima
Number HBB HPV Genotype HBB HPV Genotype
1 ++ ++, ++ HPV-56, HPV-54 ++ Negative –
2  ++ ++ HPV-51 ++ Negative –
3  +++ ++ HPV-68 ++ Negative –
4  +++ + HPV-16 ++ Negative –
5  +++ + HPV-33 ++ Negative –
6  +++ + HPV-39 ++ Negative –
7  ++ ++, + HPV-52, HPV-82 ++ + HPV-82
8  +++ +, ++, +++, + HPV-45, HPV-53, HPV-
9  +++ +, ++ HPV-68, HPV-43 
10  ++ Negative – 
Table 3
Genotyping results in Anyplex in parallel and post Aptima. Results divided in high
risk genotyping results and other genotypes.
Anyplex in parallel Anyplex post Aptima
Genotype (n) (n)
High risk genotypes HPV-16 16 15
HPV-18 3 3
HPV-31 6 6
HPV-33 3 2
HPV-35 2 2
HPV-39 4 3
HPV-45 6 4
HPV-51 3 1
HPV-52 1 –
HPV-56 5 4
HPV-58 4 3
HPV-59 1 1
HPV-66 7 6
HPV-68 4 1
Total high risk results 65 51
Other genotypes HPV-6 6 3
HPV-40 1 1
HPV-42 15 9
HPV-43 2 2
HPV-44 4 2
HPV-53 9 6
HPV-54 2 –
HPV-61 8 4
HPV-73 4 4
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Total other genotypes 53 33
rocedure for evaluating genotype in screening positive samples
an be desirable, for patient treatment and follow up. The feasibility
f using the analyzed mRNA Aptima tube compared to locating the
riginal thin prep sample proves efﬁcient in the laboratory every-
ay work. The DNA test selected for the study was the Anyplex
I HPV 28 (Seegene), a very sensitive test with a possible detec-
ion of 28 genotypes. Because of its semi-quantitative approach
ifferences in detection levels could be explored, in parallel and
fter the mRNA Aptima analysis, thereby also evaluating the cho-
en DNA test. It was important to verify that the test could be
sed for DNA testing after mRNA analysis, using minor amounts
f sample volume from the Aptima test tube. This was  done by
omparing Anyplex post Aptima to Anyplex in parallel. The DNA
xtraction proceeding the Anyplex run performed in parallel to the
ptima (from Thinprep sample) was done on a larger input volume
1000 l) whilst only 200 l was used for DNA extraction for the
nyplex post Aptima run. Although such a sensitive test may  not be
elevant for screening purposes, it can provide detailed information
or genotype speciﬁc purposes.
The study show that successful determination of HPV genotypes
an be performed when using analyzed mRNA Aptima test tubes for42, HPV-61 ++ +, +++ HPV-53, HPV-42
++ ++ HPV-43
++ + HPV-58
DNA testing. However, 4 of the 39 Aptima mRNA positive results
could not be veriﬁed to hold a high risk genotype. The mRNA HPV
Aptima testing is used to identify clinically relevant infections with
high viral oncoprotein transcript levels, possibly leading to pro-
gression, while HPV DNA presence may  be reduced due to the viral
inability to fulﬁll its lifecycle (Doorbar, 2006). The fact that 4 sam-
ples were HPV DNA negative, even with this sensitive test, might
partly be explained by the minor volume used for extraction from
the analyzed mRNA Aptima transfer test tubes (200 l). This vol-
ume  was  set to ﬁt the current extraction protocol and could be
increased accordingly. However, data from the evaluation of the
DNA genotyping method (Section 3.2 of results) show that only
one of the 4 samples was  positive when run in parallel to the mRNA
Aptima assay with a larger sample extraction volume (1000 l), i.e.
Anyplex in parallel. This sample was  positive for HPV 52 at 40 cycles.
An additional explanation for the disconcordant results could be
false positivity due to cross-reactivity, which has previously been
described for the HPV Aptima (low risk types HPV 26, 67, 70 and
82). Interestingly, one of the four samples was  detected with HPV
82 while another sample contained genotype 44.
It is shown in this study, for HPV positive samples as well as
for high risk HPV positive samples, a high concordance of results
in parallel to and after the mRNA APTIMA analysis (Cohen’s kappa
0.81, sensitivity 0.85 and 0.82 respectively and speciﬁcity 0.98).
However, nine of the high-risk positive samples detected in the
parallel Anyplex run were after mRNA Aptima analysis either low
risk positives or negatives. Several positive results were also found
at a higher cycle number, suggestive of a lower input of viral DNA in
Anyplex post Aptima compared to the Anyplex performed in par-
allel to the Aptima. As described above, this could be attributed to
the dilution effect found in the extraction proceeding Anyplex post
Aptima. If considering mRNA Aptima assay data for these samples,
all but one tested negative thereby potentially indicating permis-
sive infections rather than progressive disease.
Clinical value of HPV-16 genotyping has been shown in both
primary HPV screening as well as after cytology triage (Schiffman
et al., 2015a,b). Also, in the long-term study by Smelov et al. (2015),
increased long term risks were found not only for HPV-16 but also
for HPV 18, 31 and 33. The Hologic platform offers genotyping
for HPV- 16, 18 and 45 as a secondary analysis step re-using the
sample Aptima tube, but the possibility to extract DNA facilitates
for a wider HPV genotyping as well as for other DNA based anal-
yses. Several samples from this study contained genotypes from
the potential-or probable high risk group, i.e. HPV -53, HPV-73 and
HPV-82 and several of the high risk positive samples also contained
accompanying low-risk types. With the perspective of vaccination
effects, with its change in genotype prevalence, a broadening of
the analysis repertoire may be necessary. Also, very little research
has been put forward on concurrent low-and high risk HPV infec-
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Snijders, P.J., et al., 2004. HPV testing and monitoring of women after
treatment of CIN 3: review of the literature and meta-analysis. Obstet.
Gynecol. Surv. 59 (7), 543–553.4 G. Lillsunde Larsson et al. / Journal 
ions. Apart from genotyping, other non-morphological candidate
arkers for triage of HPV positive women are HPV methylation
nd host cell tumour suppressor gene methylation. Based on DNA,
ethylation levels of promoter regions of human genes such as cell
dhesion molecule 1 (CADM1) and T-lymphocyte maturation asso-
iated protein (MAL) (Verhoef et al., 2014) or of different viral genes
an also be assessed from the initial sample.
We acknowledge some limitations with this study. In order to
ssure sample results and detection levels, repeat testing could
ave been performed to calculate inter and intraassay variation.
lso, a larger volume of sample could have been used for extrac-
ion from the analyzed mRNA Aptima tubes to resemble the initial
ampling. However, in conclusion, the study has shown it possible
o use the processed mRNA Aptima sample tube as a source for DNA
PV genotyping using a sensitive test, such as the Anyplex II HPV
8. Before implementing the method in clinical routine, the sample
olume used for extraction needs to be further explored.
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